The Question

There is a type of blood cancer called chronic myeloid leukaemia — CML for short. In the 1990s, a diagnosis meant you had roughly five years to live. Then, in 2001, a targeted drug called imatinib arrived. Today, more than 90% of CML patients are alive ten years after diagnosis. The cancer didn't disappear. It became something people live with, not die from.

Cancer research laboratory

Our model gives this 75% probability. In England and Wales, about half of people diagnosed now survive at least ten years, up from about a quarter in the early 1970s, according to Cancer Research UK. The science is converging from four directions: immune cell therapies that use your own body to hunt cancer; personalised vaccines trained against your specific tumour; AI that catches cancer early enough to cure it; and blood tests that find tumour DNA in your bloodstream before symptoms appear. The CML story is the proof of concept. The question is how fast, and for which cancers, it can be repeated.

What the Evidence Shows

"Seven in 10 people now survive their cancer five years or more, up from only half in the mid-70s."

— Rebecca Siegel, American Cancer Society, January 2026

The trend lines are real. Overall five-year cancer survival in the US reached 70% for people diagnosed in 2015–2021, up from about half in the mid-1970s, according to the American Cancer Society's 2026 report. Five-year survival for cancers that have already spread more than doubled since the mid-1990s, from 17% to 35%. Cancer death rates have fallen by 34% since their 1991 peak — driven by less smoking, better screening, and improved treatment.

The most dramatic new tool is CAR-T therapy. Doctors take your immune cells, reprogram them in a lab to recognise and attack your cancer, then infuse them back. For blood cancers and lymphomas, it has achieved complete remission in patients who had failed every other treatment — patients who, not long ago, would have had weeks. Meanwhile, personalised mRNA cancer vaccines, built to target mutations unique to each patient's tumour, have reached a milestone. In August 2026, Merck and Moderna reported that their vaccine, intismeran autogene, given with the immunotherapy Keytruda, met its main goal in a phase 3 trial of 1,137 patients with high-risk melanoma, reducing recurrence. It was the first positive phase 3 result for an mRNA cancer therapy; full data are still to be published.

CAR-T is not a pill. It is a living drug — one that evolves inside the patient and keeps hunting cancer for years.

Detection is being transformed too. A blood test called Galleri, developed by GRAIL, looks for signs of more than 50 cancer types in a single blood draw. But the first results of the NHS-Galleri trial in England, with about 142,000 people, were mixed: the test quadrupled the number of cancers found by screening, yet it missed its main goal of reducing late-stage (stage III–IV) diagnoses, though stage IV diagnoses fell by about 14%. AI is also now reading mammograms, CT scans, and pathology slides with accuracy that matches or beats experienced radiologists. Catching cancer earlier, when it's still confined and curable, is arguably the single most powerful lever medicine has.

Why This Is Happening

The cost of these treatments is its own crisis. A single course of CAR-T therapy costs $400,000 to $500,000. Personalised mRNA vaccines, once approved, are unlikely to be priced below six figures. Even in countries with public healthcare, cancer treatment costs are straining budgets. In the US, tens of thousands of families face financial ruin from treatment bills every year. The scientific revolution and the access failure could coexist entirely — better outcomes for the wealthy, unchanged mortality for everyone else.

Racial gaps in cancer outcomes are wide and stubbornly persistent. Black and Native American people have higher cancer death rates than white Americans; Native Americans' death rates for kidney and liver cancer are about twice as high. The American Cancer Society attributes these gaps largely to unequal access to high-quality care, later diagnoses, and lower access to screening and the newest treatments. Better drugs improve the national average while leaving the most disadvantaged unchanged, unless access is deliberately addressed.

Not everyone responds to immunotherapy — and we don't yet know why. Treatments that unleash the immune system against cancer work spectacularly in some patients and do almost nothing in others. Working out who will respond before treatment starts — rather than after a futile, expensive, and toxic course — is one of oncology's most urgent unsolved problems.


What Could Happen

By 2035: Most Cancer Diagnoses Lead to 10+ Year Survival Most likely · 75%

Several major cancers — including forms of lung, breast, and colorectal cancer — join CML as conditions routinely controlled long-term rather than cured. The Galleri blood test and its successors become standard preventive health tools, shifting diagnosis towards earlier, more treatable stages. CAR-T and mRNA vaccines gain approval for a widening range of cancers. Overall five-year survival rates reach 75 to 80% in high-income countries. Access is deeply unequal — but the tools to transform cancer mortality exist and are in widespread clinical use.

By 2035: Progress Stalls — Blood Cancers Transformed, Solid Tumours Lag Possible · 25%

New therapies prove effective but narrow. CAR-T works brilliantly for blood cancers but cannot effectively penetrate solid tumours — the kind that kill most people. Personalised mRNA vaccines show real promise in trials but prove harder and more expensive to deliver at scale than expected. Overall survival rates improve slowly. The racial and economic gap in outcomes widens as new technologies flow primarily to the privately insured. The majority threshold for 10-year survival is not crossed by 2035.

By 2032: AI Detection Drives the Shift Before New Treatments Do Less likely

Early detection turns out to be the decisive factor. AI blood tests and smarter imaging shift cancer diagnoses massively towards early stages — where treatments we already have achieve high cure rates. Cancer mortality falls dramatically not because treatment improves dramatically, but because far fewer people are diagnosed at Stage 3 or 4, when the disease is already spreading. Detection test costs fall sharply by 2032, enabling population-wide screening in wealthy and middle-income countries alike.

Forecast The World Verdict
We assign 75% probability that by 2035, the majority of cancer diagnoses in high-income countries result in 10-year or longer survival — completing cancer's transition from a disease that typically kills to one most patients outlive. We have raised this forecast from 68%: about half of patients in England already reach ten years, US five-year survival has hit 70%, and the first mRNA cancer vaccine has succeeded in a phase 3 trial. The NHS-Galleri results are a caution that early detection by blood test is harder than hoped. The 25% chance we miss this milestone comes down to two risks: that revolutionary therapies prove too narrow — brilliantly effective for blood cancers but unable to crack solid tumours — and that the cost of these treatments puts them out of reach for the patients who need them most. The science is winning. The system that delivers it needs to catch up.

What Can We Do

Cancer prevention and screening

Prevention is where the real leverage is — and it's the most consistently underrated tool in cancer. Around 40 to 45% of cancer cases in wealthy countries are linked to things people can actually change: smoking, heavy drinking, obesity, physical inactivity, and certain infections. Anti-smoking campaigns have already done more to cut cancer deaths than any drug ever has. The next big frontier is obesity — the second leading preventable cause of cancer after tobacco. Weight-loss drugs like semaglutide (Ozempic) could have a significant impact on cancer incidence over the coming decade, simply by addressing one of its biggest drivers.

For you personally, the highest-return action is straightforward: get screened. Mammograms, colonoscopies, low-dose CT scans for heavy smokers, and cervical smear tests are all associated with real mortality reductions. The HPV vaccine — which most people associate with cervical cancer — also prevents cancers of the throat, anus, and penis, and coverage remains below optimal in most countries. If you or someone you know has put off a routine screening, now is the time. The treatments coming down the pipeline are most effective when the cancer is caught early. Screening is how you get there.

At the policy level, the most impactful changes would be requiring all insurers to cover participation in cancer clinical trials, increasing prevention funding relative to treatment, and negotiating international drug pricing so life-saving therapies reach lower-income countries at differential cost. The science is winning. The delivery system needs to catch up.